MC-vc-PAB-Auristatin 0101

MC-vc-PAB-Auristatin 0101 Catalog number: BADC-00740

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

MC-vc-PAB-Auristatin 0101 is a drug-linker conjugate for ADC by using Auristatin 0101 (an auristatin microtubule inhibitor), linked via MC-vc-PAB.

Category
ADCs Cytotoxin with Linkers
Product Name
MC-vc-PAB-Auristatin 0101
Catalog Number
BADC-00740
Molecular Formula
C68H100N12O14S
Molecular Weight
1341.68
MC-vc-PAB-Auristatin 0101

Ordering Information

Catalog Number Size Price Quantity
BADC-00740 -- $-- Inquiry
Description
MC-vc-PAB-Auristatin 0101 is a drug-linker conjugate for ADC by using Auristatin 0101 (an auristatin microtubule inhibitor), linked via MC-vc-PAB.
Synonyms
MC-vc-PAB-PF-06380101
Shipping
Room temperature, or blue ice upon request.
Storage
-20°C

MC-vc-PAB-Auristatin 0101 is a potent peptide-drug conjugate (PDC) designed for targeted cancer therapy. One of its key applications is in selective tumor targeting. The conjugate features a cleavable valine-citrulline (vc) linker that is specifically recognized by proteases overexpressed in the tumor microenvironment. This allows for the precise release of auristatin 0101, a cytotoxic agent that disrupts microtubule dynamics, leading to cell cycle arrest and apoptosis in cancer cells. By selectively activating the drug in tumor cells, MC-vc-PAB-Auristatin 0101 minimizes off-target toxicity and enhances therapeutic efficacy.

Another critical application of MC-vc-PAB-Auristatin 0101 is in improving the pharmacokinetics of the drug. The conjugate's structure is designed to optimize circulation time, ensuring better bioavailability and enhanced tumor accumulation. The peptide component of the conjugate allows for selective targeting, while the addition of the cleavable linker ensures that the cytotoxic drug is released only at the tumor site. This combination leads to increased drug concentration in cancerous tissues and more effective treatment, while avoiding rapid clearance and minimizing systemic exposure.

MC-vc-PAB-Auristatin 0101 is also promising in combination cancer therapies. When used in conjunction with other therapeutic agents, such as immune checkpoint inhibitors or other chemotherapy drugs, the conjugate can enhance overall treatment efficacy. Auristatin 0101’s ability to disrupt microtubule formation synergizes well with the immune-modulating effects of checkpoint inhibitors, potentially improving the response in tumors that are resistant to conventional treatments. This makes MC-vc-PAB-Auristatin 0101 a valuable tool in combination therapy strategies aimed at achieving better clinical outcomes.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Why Choose BOC Sciences?

Customer Support

Providing excellent 24/7 customer service and support

Project Management

Offering 100% high-quality services at all stages

Quality Assurance

Ensuring the quality and reliability of products or services

Global Delivery

Ensuring timely delivery of products worldwide

Questions & Comments
Verification code
Send Inquiry
Verification code
Resources & Supports
Inquiry Basket